Caracterización clínico epidemiológico de la COVID-19 en pacientes de Gibara, Holguín, abril 2020 / Epidemic and clinical characterization of COVID-19 patients from Gibara, Holguin, April, 2020

Argelio Hernandez Pupo, Jose Rafael Escalona Aguilera, Delia Tamayo Parra, Diamela Hernández Mariño, Elizabeth Mairelis Hernandez Perez

Texto completo:

PDF

Resumen

Objetivo: caracterizar el comportamiento clínico epidemiológico en
pacientes portadores de la COVID-19 de Gibara, Holguín, durante
el período comprendido desde 1 hasta el 30 de abril de 2020.

Materiales y métodos: se realizó una investigación de serie de
casos, para caracterizar el comportamiento de la COVID-19 en
pacientes del municipio de Gibara, Holguín, durante el período
comprendido desde 1 hasta el 30 de abril de 2020. El universo
estuvo constituido por todos los casos confirmados con el virus
SARS-CoV2. Los datos fueron tomados de los informes estadísticos
de la Unidad Municipal de Higiene y Epidemiología y de la encuesta
aplicada a todos los pacientes.

Resultados: el estudio incluyó a 30 pacientes. Presentaron
evolución clínica estable 28 casos y falleció un paciente para una
tasa de letalidad del 3,33%; 14 de ellos resultaron asintomáticos
(46,66%). Los síntomas más frecuentes fueron: tos y fiebre,
con 11 casos (36,66%), respectivamente; 26 pacientes fueron
autóctonos, contacto de caso positivo (86,67%). Los consejos
populares de la ciudad cabecera municipal presentaron el 80% de
los casos y una tasa del 31,15 por 105.

Conclusiones: la COVID-19 en Gibara tuvo un mayor
comportamiento en el sexo masculino y el grupo etario de 19 a
40 años. Más de las tres cuartas partes de los pacientes están
recuperados, más de la mitad estaban asintomáticos, la tos fue el
síntoma más presentado y los consejos populares de la ciudad de
Gibara, tuvieron más de las tres cuartas partes de los casos.

Palabras clave: COVID-19; epidemiología; sintomatología.

ABSTRACT

Objective: to characterize the epidemic and clinical behavior in
patients suffering from COVID-19 in Gibara, Holguín, in April 2020.

Materials and methods: a research of series of cases was carried
out to characterize the behavior of the COVID-19 in patients of the
municipality of Gibara, Holguín from April 1st to the 30th, 2020.
The universe was all the confirmed cases with SARS-CoV2 virus.
The data were taken from the statistical reports of the Municipal
Unit of Hygiene and Epidemiology, and from the survey applied to
all the patients.

Results: the study included 30 patients, 28 cases presented a
stable clinical evolution and there was a deceased, for a lethal rate
of 3,33%; there were 14 asymptomatic patients, which represents
46,66%. The most frequent symptoms were: cough and fever in
11 cases, 36.66%; 26 patients were autochthonous contacts of
positive cases (86,67%). The local neighborhoods from the city
center had 80% of the cases and a rate of 31.15 X 105.

Conclusions: the COVID-19 in Gibara had more influence in the
males, and the most affected age group was from 19 to 40. More
than three quarter of the patient are already recovered, more
than half were asymptomatic, the cough was the most common
symptom and the local neighborhhoods of the city had more than
three quarters of the cases.

Keywords: COVID-19; epidemiology; symptoms.

Palabras clave

coronavirus, epidemiología

Referencias

Li JY, You Z, Wang Q, Zhou ZJ, Qiu Y, Luo R, Ge XY. The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future, Microbes and Infection. https://doi.org/10.1016/j.micinf.2020.02.002

World Health Organization. Coronavirus disease (COVID-19) outbreak.Ginebra: WHO, 2020 [citado febrero 2020]. Disponible en: https://www.who.int/emergencies/diseases/novel-coronavirus-2019

Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory síndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents. 2020: 105924. DOI: 10.1016/j.ijantimicag.2020. 105924.

Li F, Li W, Farzan M, Harrison SC. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science. 2005; 309(5742): 1864-8.

Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020: 102433. DOI: 10.1016/j.jaut.2020.102433.

Sohrabi C, Alsafi Z, O'Neill N, Khan M, Kerwan A, Al-Jabir A et al.. World Health Organization declares Global Emergency: A review of the 2019 Novel Coronavirus (COVID-19). Int J Surg. 2020.pii: S1743-9191(20)30197-7. DOI: 10.1016/j.ijsu.2020.02.034.

Sun P, Lu X, Xu C, Sun W, Pan B. Understanding of COVID-19 based on current evidence. J Med Virol. 2020. DOI: 10.1002/jmv. 25722.

Chen Y, Liu Q, Guo D. Coronaviruses: genome structure, replication, and pathogenesis. J Med Virol. 2020. DOI: 10.1002/jmv.25681.

Han Q, Lin Q, Jin S, You L. Recent insights into 2019-nCoV: a brief but comprehensive review. J Infect. 2020. pii: S0163-4453(20)30087-6. DOI: 10.1016/j.jinf.2020.02.010.

Minsap. Nota informativa sobre la COVID-19 en Cuba: 1 de mayo. Disponible en: https://temas.sld.cu/coronavirus/category/actualidades/nota-informativa-del-minsap/

Zhang W (2020). Estimating the presymptomatic transmission of COVID19 using incubation period and serial interval. MedRxiv. DOI: https://doi.org/10.1101/2020.04.02.20051318

Du Z, Xu X, Wu Y, et al (2020). Serial interval of COVID-19 among publicly reported confirmed cases. Emerg Infect Dis. 2020 https://doi.org/10.3201/eid2606.200357

Wei WE, Li Z, Chiew CJ, et al. (2020). Presymptomatic Transmission of SARS-CoV-2 — Singapore, January 23–March 16, 2020. Morbidity and Mortality Weekly Report. 69

World Health Organization. Infection prevention and control during health care when novel coronavirus (nCoV) infection is suspected. Interim Guidance Geneva2020.

WHO/2019-nCoV/IPC/v2020.1. Disponible en: https://www.who.int/publications-detail/infection-prevention-and-control-during-health-care-when-novelcoronavirus-(ncov)-infection-is-suspected

Centers for Disease Control and Prevention. Interim Infection Prevention and Control Recommendations for Patients with Known or Patients Under Investigation for 2019 Novel

Coronavirus (2019-nCoV) in a Healthcare Setting: CDC; 2020. Disponible en: https://www.cdc.gov/coronavirus/2019-nCoV/hcp/infection-control.html

Public Health England. Wuhan novel coronavirus (WN-CoV) infection prevention and control guidance 2020. Disponible en:https://www.gov.uk/government/ publications/ wuhan-novelcoronavirus-infection-prevention-and-control/wuhan-novel-coronavirus-wn-cov-infection-prevention-and-controlguidance

Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020. doi: S0140-6736(20)30317-2 [pii].

Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in wuhan, china. JAMA. 2020. https://doi.10.1001/jama.2020.1585

Na Zhu, Zhang D, Wang W, Xingwang L, Bo Yang, Jingdong S, et al. A novel coronavirus from patients with pneumonia in China, 2019. Engl J Med. 2020;382:727-33. https://doi.org/10.1056/NEJMoa2001017

World Health Organization. Coronavirus disease (COVID-19) outbreak. Ginebra: WHO, 2020 [citado febrero 2020]. Disponible en: https://www.who.int/emergencies/diseases/novel-coronavirus-2019

Enlaces refback

  • No hay ningún enlace refback.


Copyright (c) 2020 Panorama. Cuba y Salud

Licencia de Creative Commons
Este obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial 4.0 Internacional.